AFT Pharmaceuticals (NZX; AFT, ASX; AFP) has today appointed Anita Baldauf as a non-executive director.
The appointment fills the vacancy left by Nathan Hukill who, as president of the company’s former major shareholder CRG, resigned in June 2020 following CRG’s sale of its shareholding in AFT.
Chair David Flacks says: “We are delighted to welcome Anita to the Board. She brings an outstanding mix of experience in international business development, finance, compliance, personnel development and governance through her 22-year career with Nestlé.
“More recently she has been advising New Zealand start-ups and new ventures as they navigate through the challenges of growth and changing market environments.
“All of this is directly relevant to AFT as we grow and consolidate our presence in Australasia and build our presence internationally with our Maxigesic® pain relief and other medications,” Mr Flacks said.
Ms Baldauf says she is looking forward to supporting the board, Managing Director Dr Atkinson and the AFT team to continue its strong growth trajectory.
“Since coming to New Zealand 18 months ago, I have observed AFT and consider it a shining example of Kiwi ingenuity and entrepreneurship,” Ms Baldauf says.
“Over more that two decades Hartley and the team have carved out a significant share of pharmaceutical markets in Australasia and a growing share globally.
“They have achieved this with smart ideas that are backed up by robust clinical research. I am looking forward to working with the team on the next phase of this exciting journey.”
Ms Baldauf, who is also a fellow of the Edmund Hillary Fellowship, an organisation aimed at developing solutions to global problems, will stand for re-election to the board at next year’s Annual Shareholders Meeting.
For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer.
For more information:
Dr Hartley Atkinson
Tel: +64 9488 0232
Tel: +64 21 645 643
About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com.